Neurosurgery Blog: Incidence and Mortality of Ischemic Stroke Subtypes in Joinville, Brazil: A Population-Based Study (I10-1.004)

Monday, April 14, 2014

Incidence and Mortality of Ischemic Stroke Subtypes in Joinville, Brazil: A Population-Based Study (I10-1.004)

Neurology recent issues

OBJECTIVE:Our aim was to measure the incidence and mortality rates of IS subtypes and associated vascular risk factors in Joinville, Brazil. BACKGROUND: There is a scarcity of data on the epidemiology of ischemic stroke (IS) subtypes, particularly among Latin American populationsDESIGN/METHODS: From the Joinville Stroke Registry, an ongoing population-based data bank, we identified all first-ever IS that occurred in Joinville from January 2005 to December 2006. The IS subtypes were classified by the TOAST criteria, and the patients were followed-up for one year after IS onset.RESULTS: The age-adjusted incidence per 100,000 inhabitants was 26(17-39) for large-artery atherosclerosis (LAA), 17(11-27) for cardioembolic (CE), 29(20-41) for small-artery occlusion (SAO), 2(0.6-7) for stroke of other determined etiology (OTH) and 30(20-43) for stroke of undetermined etiology (UND). The most prevalent modifiable risk fator in all IS subtypes was hypertension (70%). The 1-year mortality rate per 100,000 inhabitants was 5(2-11) for LAA, 6(3-13) for CE, 1(0.1-6) for SVO, 0.2(0-0.9) for OTH and 9(4-17) for UND. In patients over 44 years of age, men had higher incidence rates for LAA than women 100(80-122) vs. 58(44-75).CONCLUSIONS: In the predominantly White population of Joinville, the incidences of IS subtypes were similar to those found in other populations. In patients older than 44 years, men had a higher incidence of LAA than women. These findings highlight the importance of better detection and control of atherosclerotic risk factors.Study Supported by: Fundação de Amparo a Pesquisa do Estado de Santa Catarina, University of the Region of Joinville and the Joinville Municipal Health Department.

Disclosure: Dr. Lange has nothing to disclose. Dr. Cabral has nothing to disclose. Dr. Moro has nothing to disclose. Dr. Longo has nothing to disclose. Dr. Goncalves has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Rundek has nothing to disclose.

Original Article: http://www.neurology.org/cgi/content/short/82/10_Supplement/I10-1.004?rss=1